Back to top
more

Akebia Therapeutics (AKBA)

(Delayed Data from NSDQ)

$1.34 USD

1.34
2,474,352

+0.01 (0.75%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.33 -0.01 (-0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

by Zacks Equity Research

Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 100% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -100% and 4.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 124.39% and 14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 25% and 11.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging InMode (INMD) This Year?

by Zacks Equity Research

Here is how InMode (INMD) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

KalVista (KALV) Surges 15% on Update From Angioedema Study

by Zacks Equity Research

KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.

Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%

by Zacks Equity Research

Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.

Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%

by Zacks Equity Research

Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.

Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera

by Zacks Equity Research

Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year.

Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data

by Zacks Equity Research

New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.

All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy

by Zacks Equity Research

Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?

by Zacks Equity Research

Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 6.67% and 14.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

CTI BioPharma (CTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 71.43% and 14.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Plus (PSTV) delivered earnings and revenue surprises of -6.67% and 88.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

by Zacks Equity Research

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?